scholarly journals History and Future Perspectives on the Discipline of Quantitative Systems Pharmacology Modeling and Its Applications

2021 ◽  
Vol 12 ◽  
Author(s):  
Karim Azer ◽  
Chanchala D. Kaddi ◽  
Jeffrey S. Barrett ◽  
Jane P. F. Bai ◽  
Sean T. McQuade ◽  
...  

Mathematical biology and pharmacology models have a long and rich history in the fields of medicine and physiology, impacting our understanding of disease mechanisms and the development of novel therapeutics. With an increased focus on the pharmacology application of system models and the advances in data science spanning mechanistic and empirical approaches, there is a significant opportunity and promise to leverage these advancements to enhance the development and application of the systems pharmacology field. In this paper, we will review milestones in the evolution of mathematical biology and pharmacology models, highlight some of the gaps and challenges in developing and applying systems pharmacology models, and provide a vision for an integrated strategy that leverages advances in adjacent fields to overcome these challenges.

Author(s):  
Peter Bloomingdale ◽  
Tatiana Karelina ◽  
Murat Cirit ◽  
Sarah F. Muldoon ◽  
Justin Baker ◽  
...  

2018 ◽  
Vol 104 (5) ◽  
pp. 798-798
Author(s):  
Kevin Blake ◽  
Milton Bonelli ◽  
Stefano Ponzano ◽  
Harald Enzmann ◽  

Cancers ◽  
2021 ◽  
Vol 13 (15) ◽  
pp. 3751
Author(s):  
Chang Gong ◽  
Alvaro Ruiz-Martinez ◽  
Holly Kimko ◽  
Aleksander S. Popel

Quantitative systems pharmacology (QSP) models have become increasingly common in fundamental mechanistic studies and drug discovery in both academic and industrial environments. With imaging techniques widely adopted and other spatial quantification of tumor such as spatial transcriptomics gaining traction, it is crucial that these data reflecting tumor spatial heterogeneity be utilized to inform the QSP models to enhance their predictive power. We developed a hybrid computational model platform, spQSP-IO, to extend QSP models of immuno-oncology with spatially resolved agent-based models (ABM), combining their powers to track whole patient-scale dynamics and recapitulate the emergent spatial heterogeneity in the tumor. Using a model of non-small-cell lung cancer developed based on this platform, we studied the role of the tumor microenvironment and cancer–immune cell interactions in tumor development and applied anti-PD-1 treatment to virtual patients and studied how the spatial distribution of cells changes during tumor growth in response to the immune checkpoint inhibition treatment. Using parameter sensitivity analysis and biomarker analysis, we are able to identify mechanisms and pretreatment measurements correlated with treatment efficacy. By incorporating spatial data that highlight both heterogeneity in tumors and variability among individual patients, spQSP-IO models can extend the QSP framework and further advance virtual clinical trials.


Sign in / Sign up

Export Citation Format

Share Document